Several studies have shown that combining IMiDs with immunosuppressive steroids, proteasome inhibitors, or EZH2 inhibitors significantly improves overall survival rates in the treatment of both newly diagnosed and R/R MM [23,41,42], emphasizing the advantages of a combinational therapeutic strategy for hematological cancers. This evidence concerns the gene EZH2 and hematopoietic and lymphoid cell neoplasm.